期刊
VIRUSES-BASEL
卷 15, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/v15071533
关键词
monkeypox virus (MPXV); human monkeypox (HMPX); epidemiology; MPXV pathophysiology; diagnosis; therapeutics
类别
An outbreak of monkeypox, caused by a double-stranded DNA virus, has become a global public health emergency. This report summarizes new knowledge on the epidemiology, pathology, and prevention strategies of monkeypox, including diagnosis, clinical management, vaccines, and antiviral drugs. The re-emergence of monkeypox highlights the need to reassess current clinical strategies and therapeutics.
An enveloped double-stranded DNA monkeypox virus (MPXV) is a causative agent of the zoonotic viral disease, human monkeypox (HMPX). MPXV belongs to the genus Orthopoxviridae, a family of notorious smallpox viruses, and so it shares similar clinical pathophysiological features. The recent multicountry HMPX outbreak (May 2022 onwards) is recognized as an emerging global public health emergency by the World Health Organization, shunting its endemic status as opined over the past few decades. Re-emergence of HMPX raises concern to reassess the present clinical strategy and therapeutics as its outbreak evolves further. Keeping a check on these developments, here we provide insights into the HMPX epidemiology, pathophysiology, and clinical representation. Weighing on its early prevention, we reviewed the strategies that are being enrolled for HMPX diagnosis. In the line of expanded MPXV prevalence, we further reviewed its clinical management and the diverse employed preventive/therapeutic strategies, including vaccines (JYNNEOS, ACAM2000, VIGIV) and antiviral drugs/inhibitors (Tecovirimat, Cidofovir, Brincidofovir). Taken together, with a revised perspective of HMPX re-emergence, the present report summarizes new knowledge on its prevalence, pathology, and prevention strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据